Crystalline form of deuruxolitinib phosphate
The present disclosure is directed to polymorph Form 1 of 1H-pyrazole-1-propanenitrile, β-(cyclopentyl-2,2,3,3,4,4,5,5-d 8 )-4-(7H-pyrrolo[2,3- d ]pyrimidin-4- yl )-, (βR)-, phosphate (1:1) (deuruxolitinib phosphate). Also disclosed are methods of treatment using polymorph Form 1 of deuruxolitinib phosphate and methods of making polymorph Form 1 of deuruxolitinib phosphate.
1. A polymorph of a compound of Formula I:
wherein the polymorph is Form I; and
wherein Form I is characterized by a powder X-ray diffraction pattern comprising at least three peaks at angles (°2θ) selected from 4.03°±0.2°2θ, 14.54°±0.2°2θ, 24.95°±0.2°2θ, and 25.29°±0.2°2θ.
2. The polymorph of claim 1 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising peaks at angles (°2θ) of 4.03°±0.2°2θ, 14.54°±0.2°2θ, 24.95°±0.2°2θ, and 25.29°±0.2°2θ.
3. The polymorph of claim 2 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising at least one additional peak at an angle (°2θ) selected from 14.77°±0.2°2θ, 20.87°±0.2°2θ, 21.76°±0.2°2θ, and 26.36°±0.2°2θ.
4. The polymorph of claim 2 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising at least two additional peaks at angles (°2θ) selected from 14.77°±0.2°2θ, 20.87°±0.2°2θ, 21.76°±0.2°2θ, and 26.36°±0.2°2θ.
5. The polymorph of claim 2 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising at least three additional peaks at angles (°2θ) selected from 14.77°±0.2°2θ, 20.87°±0.2°2θ, 21.76°±0.2°2θ, and 26.36°±0.2°2θ.
6. The polymorph of claim 2 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising four additional peaks at angles (°2θ) of 14.77°±0.2°2θ, 20.87°±0.2°2θ, 21.76°±0.2°2θ, and 26.36°±0.2°2θ.
7. The polymorph of claim 1 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising at least one additional peak at an angle (°2θ) selected from 7.55°±0.2°2θ, 8.36°±0.2°2θ, 15.94°±0.2°2θ, and 20.41°±0.2°2θ.
8. The polymorph of claim 1 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising at least two additional peaks at angles (°2θ) selected from 7.55°±0.2°2θ, 8.360°±0.2°2θ, 15.940°±0.2°2θ, and 20.41°±0.2°2θ.
9. The polymorph of claim 1 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern comprising at least three additional peaks at angles (°2θ) selected from 7.55°±0.2°2θ, 8.360°±0.2°2θ, 15.94°±0.2°2θ, and 20.41°±0.2°2θ.
10. The polymorph of claim 1 , wherein the polymorph is further characterized by a powder X-ray diffraction pattern as shown in FIG. 1 .
11. The polymorph of claim 1 , wherein the polymorph is further characterized by at least one of (a), (b), and (c):
(a) a differential scanning calorimetry (DSC) spectrum (10° C./min) comprising an endotherm onset at 194.3° C.±1.0° C. and peak at 197.4° C.±1.0° C.;
(b) a Fourier transform (FT)-Raman spectrum as depicted in FIG. 3 ; and
(c) a thermogravimetric-Fourier transform infrared (TG-FTIR) thermogram as depicted in FIG. 4 .
12. The polymorph of claim 11 , wherein the polymorph Is further characterized by at least 90% deuterium incorporation at each of the specified deuterated positions, as determined by 1 H-NMR.
13. The polymorph of claim 11 , wherein the polymorph Is further characterized by at least 95% deuterium incorporation at each of the specified deuterated positions, as determined by 1 H-NMR.
14. A pharmaceutical composition comprising the polymorph of claim 1 and a pharmaceutically acceptable carrier.